期刊文献+

补康灵预防非小细胞肺癌化疗后白细胞减少症的疗效观察 被引量:3

Clinical Observation of Bukangling on Preventing Leucopenia of NSCLC Caused by Chemotherapy
原文传递
导出
摘要 目的:观察补康灵预防非小细胞肺癌患者化疗后白细胞减少症的疗效。方法:将120例非小细胞肺癌初治患者随机分为两组,治疗组63例,采用TP方案化疗,联合口服补康灵治疗;对照组57例仅采用TP方案化疗,观察化疗期间两组白细胞的变化、重组人粒细胞集落刺激因子(G-CSF)使用量、白细胞减少继发感染发生情况及生活质量评分情况。结果:治疗组在化疗过程中白细胞减少20例(31.75%)明显少于对照组34例(59.65%)(P<0.05),两组G-CSF用量、生活质量改善状况以及白细胞减少继发感染发生例数之间的均有统计学差异(P<0.05)。结论:补康灵可有效预防非小细胞肺癌化疗所发生的白细胞减少症。 Objective: To observe the effect and adverse reaction of Bukangling on preventing leucopenia of NSCLC caused by chemotherapy. Methods : 120 patients were randomized into two groups : the treatment group ( 63 cases) were treated with TP chemotherapy and Bukangling while the control group(57 cases)treated with TP chemotherapy only. Dur- ing chemotherapy, the patients were evaluated on situations of WBC, the volume of G - CSF, the secondary infection asso- ciated with leucopenia and score of life - quality in two groups. Results : Leucopenia patients in treatment group were nota- bly lower than that in control group [ 20 cases (31.75%)vs 34 cases (59.65%) ], the difference in the volume of G - CSF, the secondary infection associated with leucopenia and score of life - quality in two groups were statistically signifi- onnt( P 〈'D D~'~ C,3nelrL.~i,3n. Ruknn~,lin~ i~ nn ~ffe^etivf~ dru~ used in nreventin~ leuconenia caused hv chemotheranv.
出处 《中华中医药学刊》 CAS 2012年第6期1315-1316,共2页 Chinese Archives of Traditional Chinese Medicine
基金 江苏省卫生厅医学科技发展基金资助项目(P200939)
关键词 补康灵 非小细胞肺癌 化疗 白细胞减少 Bukangling NSCLC chemotherapy leucopenia
  • 相关文献

参考文献5

二级参考文献37

共引文献38

同被引文献26

  • 1郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,1993.70.
  • 2沈自尹.中医虚证辨证参考标准.中西医结合杂志,1989,9:11-11.
  • 3Kim YS, Sun JM, Ahn JS, et al. The optimal, duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer [ J]. Lung Cancer, 2013, 81 (2) : 231-235.
  • 4Komaki R, Wei X, Allen PK, et al. Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer[ J ]. Front Oncol, 2011,1:52.
  • 5Lau DH, Moon J, Davies AM, et al. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma [ J ]. Clin Lung Cancer, 2013, 14(4): 351-355.
  • 6Manegold C, Vansteenkiste J, Cardenal F, et at. Randomized phase 1I study of three doses of the integrin inhibitor cilenitide versus docetaxel as second-line treatment for patients with ad- vanced non-small-cell lung cancer[J]. Invest New Drugs, 2013, 31(1) : 175-182.
  • 7徐娅.十全大补汤加味治疗化疗骨髓抑制临床观察[J].实用中医药杂志,2008,24(4):210-211. 被引量:12
  • 8支修益.我国肺癌流行病学现状分析[J].中国处方药,2009,8(2):56-57. 被引量:99
  • 9王烨珣.rhG-CSF防治晚期肺癌化疗后白细胞减少的疗效[J].实用药物与临床,2010,13(1):71-72. 被引量:15
  • 10梁芳.生脉注射液联合清开灵注射液治疗晚期非小细胞肺癌恶病质20例[J].环球中医药,2010,3(2):138-139. 被引量:5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部